M&A aftermath Leverage the Thermo Fisher acquisition of PPD to position Evidera solutions as the integrated real-world evidence and health economics arm that complements Thermo Fisher's lab and services, targeting life sciences customers seeking end-to-end development, evidence generation, and market access support.

Expansion momentum Capitalize on recent headcount growth and lab footprint expansion in Kentucky to map new clinical research and real-world data capabilities for regional pharma and biotech clients, emphasizing capacity, faster timelines, and geographic coverage.

underserved focus Target collaborations with initiatives like Alliance for Representative Clinical Trials and NMQF partnerships to offer Evidera's patient-centered evidence solutions to historically underserved populations, opening access contracts with sponsors seeking diversity in real-world data.

Integrated tech Highlight the use of a diversified tech stack including analytics, data governance, and digital training capabilities to differentiate offerings in health economics, market access, and patient research, presenting a turnkey solution for sponsors needing complex, compliant data workflows.

Financial fit Position mid-market life sciences firms with $50M-$100M revenue as primary targets, aligning Evidera’s value in accelerating evidence generation and regulatory/support processes to clients seeking cost-effective, scalable real-world evidence and HEOR services.